882182-35-6

Basic information

• Product Name: 2-methyl-2-(((1S)-1-phenylethyl)amino)propanenitrile
• Synonyms: 2-methyl-2-(((1S)-1-phenylethyl)amino)propanenitrile
• CAS NO: 882182-35-6
• Molecular Weight: 188.272
• Mol File: 882182-35-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-methyl-2-(((1S)-1-phenylethyl)amino)propanenitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 2-methyl-2-(((1S)-1-phenylethyl)amino)propanenitrile(882182-35-6)
• EPA Substance Registry System: 2-methyl-2-(((1S)-1-phenylethyl)amino)propanenitrile(882182-35-6)

Safety Data

• Hazardous Substances Data: 882182-35-6(Hazardous Substances Data)

Upstream product

• 2627-86-3 (S)-1-phenyl-ethylamine 
• 75-86-5 2-hydroxy-2-methylpropanenitrile 
• 638-65-3 stearonitrile 
• 2141-62-0 3-(ethoxy)propionitrile 
• 75-05-8 acetonitrile 
• 104-47-2 p-methoxybenzylnitrile 
• 104-85-8 para-methylbenzonitrile 
• 100-47-0 benzonitrile 
• 555-21-5 4-Nitrophenylacetonitrile 
• 140-29-4 phenylacetonitrile 
• 766-05-2 cyclohexane carbonitrile 
• 3598-14-9 phenoxyacetonitrile 
• 7498-57-9 2-naphthaleneacetonitrile 
• 646-20-8 pimelonitrile 

Downstream Products

• 882182-36-7 7-((1S)-1-phenylethyl)-7-azabicyclo[2.2.1]heptane-1-carbonitrile 
• 1268852-15-8 (3aR,6aR)-1-[(1S)-1-phenylethyl]hexahydrocyclopenta[b]pyrrole-6a(1H)-carbonitrile 
• 1268852-13-6 (3aS,6aS)-1-[(1S)-1-phenylethyl]hexahydrocyclopenta[b]pyrrole-6a(1H)-carbonitrile 

Relevant articles and documents

Stereoselective synthesis of 2,4-methanoproline homologues

The stereoselective synthesis of 2-azabicyclo[2.2.1]heptane-1-carboxylic acid and 6-azabicyclo[3.2.1]octane-5-carboxylic acid, novel rigid bicyclic proline analogues, is reported. The synthesis was performed in five steps from the corresponding 2-cycloalk

NOVEL INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)

A compound having the structure set forth in Formula (I): wherein the variables Y, R1, R2, R3, R4 and R5 are as defined herein. Compounds described herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of such compounds and pharmaceutical compositions to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity